Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118183354 | 11818335 | 4 | F | 201106 | 20160630 | 20151210 | 20160711 | PER | US-JNJFOC-20151108005 | JANSSEN | 13.29 | YR | A | M | Y | 0.00000 | 20160711 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118183354 | 11818335 | 1 | SS | RISPERDAL | RISPERIDONE | 1 | Oral | U | U | 0 | 1 | MG | UNSPECIFIED | ||||||
| 118183354 | 11818335 | 2 | SS | RISPERDAL | RISPERIDONE | 1 | Oral | U | U | 0 | 1 | MG | UNSPECIFIED | ||||||
| 118183354 | 11818335 | 3 | SS | RISPERDAL | RISPERIDONE | 1 | Oral | U | U | 0 | 2 | MG | UNSPECIFIED | ||||||
| 118183354 | 11818335 | 4 | PS | RISPERDAL | RISPERIDONE | 1 | Oral | U | U | 20272 | 1 | MG | UNSPECIFIED | ||||||
| 118183354 | 11818335 | 5 | SS | INVEGA | PALIPERIDONE | 1 | Oral | U | U | 0 | 3 | MG | OROS (ORAL OSMOTIC) THERAPEUTIC SYSTEM TABLET | ||||||
| 118183354 | 11818335 | 6 | SS | INVEGA | PALIPERIDONE | 1 | Oral | U | U | 0 | 3 | MG | OROS (ORAL OSMOTIC) THERAPEUTIC SYSTEM TABLET | ||||||
| 118183354 | 11818335 | 7 | SS | INVEGA | PALIPERIDONE | 1 | Oral | U | U | 0 | 3 | MG | OROS (ORAL OSMOTIC) THERAPEUTIC SYSTEM TABLET | ||||||
| 118183354 | 11818335 | 8 | SS | INVEGA | PALIPERIDONE | 1 | Oral | U | U | 21999 | 3 | MG | OROS (ORAL OSMOTIC) THERAPEUTIC SYSTEM TABLET | ||||||
| 118183354 | 11818335 | 9 | SS | RISPERIDONE. | RISPERIDONE | 1 | Unknown | U | 0 | TABLETS |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118183354 | 11818335 | 1 | Attention deficit/hyperactivity disorder |
| 118183354 | 11818335 | 2 | Attention deficit/hyperactivity disorder |
| 118183354 | 11818335 | 3 | Attention deficit/hyperactivity disorder |
| 118183354 | 11818335 | 4 | Attention deficit/hyperactivity disorder |
| 118183354 | 11818335 | 5 | Attention deficit/hyperactivity disorder |
| 118183354 | 11818335 | 6 | Attention deficit/hyperactivity disorder |
| 118183354 | 11818335 | 7 | Attention deficit/hyperactivity disorder |
| 118183354 | 11818335 | 8 | Attention deficit/hyperactivity disorder |
| 118183354 | 11818335 | 9 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118183354 | 11818335 | Gynaecomastia | |
| 118183354 | 11818335 | Off label use | |
| 118183354 | 11818335 | Product use issue | |
| 118183354 | 11818335 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 118183354 | 11818335 | 1 | 201201 | 201212 | 0 | |
| 118183354 | 11818335 | 2 | 201111 | 201112 | 0 | |
| 118183354 | 11818335 | 3 | 201106 | 201111 | 0 | |
| 118183354 | 11818335 | 4 | 201301 | 201401 | 0 | |
| 118183354 | 11818335 | 5 | 201012 | 201105 | 0 | |
| 118183354 | 11818335 | 6 | 201007 | 201011 | 0 | |
| 118183354 | 11818335 | 7 | 200909 | 201006 | 0 | |
| 118183354 | 11818335 | 8 | 200906 | 200908 | 0 |